Theravance Biopharma Inc (TBPH)
NASDAQ • Healthcare
Last close at September 25, 2026 at 20:00 UTC
Metrics Over Time
Where the Money Goes
Q2 2026In plain terms: out of every $100 in revenue, Theravance Biopharma Inc currently loses $28.
Fundamentals & Financials
TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.
Income Statement
Balance Sheet
Financial Highlights
Dividends History
Split History
Earnings
% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS
Theravance Biopharma’s second fiscal quarter of 2026 results trailed consensus on revenue, based on preliminary figures reported August 10, 2026. Revenue fell 20.9% year over year to about $20.7 million (down from $26.2 million a year ago), and it trailed expectations with revenue of $20.7 million versus the $22.5 million estimate (-8%). The business is driven by its respiratory franchise led by YUPELRI in the U.S. On cash generation, the company posted negative operating cash flow of roughly $8.9 million for the quarter. Consensus for the next period calls for EPS of $0.24 on revenue of $22.0 million.
Next report — what to expect
Theravance Biopharma Inc (TBPH) reports earnings on November 10, 2026. Wall Street’s next-period consensus calls for EPS of $0.24 on revenue of $22.0 million. For trailing context, revenue fell -20.9% year over year last quarter. TBPH has beaten EPS in 2 of its 8 most recent quarters.
About Theravance Biopharma Inc
Theravance Biopharma Inc is a NASDAQ-listed biotechnology company focused on respiratory and other specialty medicines in the United States. FY2025 revenue was $107.5 million. Its marketed product is YUPELRI, a once-daily nebulized long-acting muscarinic antagonist for COPD, while Ampreloxetine remains an investigational once-daily norepinephrine reuptake inhibitor.
Today's Snapshot
The day ended with TBPH flat at 17.03, while its sector was weaker. Volume was several times its usual level.
Trading Volume
Above 10d avg 1.9M
10M
vs S&P 500 Today
Outperforming Market
+0.52%
Updated: October 23, 2026 at 20:28 UTC
Technical Indicators
All signalsHide signals
- EMA (5 indicators)$16.92 - $17.10Buy
- RSI (14)53.24Neutral
- Stochastic %K (14, 3, 3)17.69Buy
- MACD Level (12, 26)0.02Neutral
Peers & Related Assets
Get premium market insights delivered directly to your inbox.